Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinx‘Ozempic Penis’ Could Push Patients Toward Risky Peptide Stacks

🎓 Expert Commentary / Peer Perspective

Patients are increasingly asking whether GLP-1 therapy increases penile size. Experts cited in the article attribute reported changes primarily to weight-loss related body composition changes and improved erectile quality, while available evidence remains limited and mixed.


Patient Counseling Points

  • No clinical evidence currently demonstrates GLP-1 receptor agonists enlarge penile tissue.
  • Weight loss may reveal previously obscured shaft length without anatomical penile growth.
  • Improved cardiometabolic health may contribute to perceived changes in erection quality or girth.
  • Viral claims may encourage interest in off-label peptide stacking despite limited safety and efficacy evidence.

Patient Care Applications

  • Reassure patients that reported changes do not establish penile tissue growth.
  • Interpret viral health claims within available evidence and physiologic mechanisms.
  • Ask about peptide use, testosterone products, and sexual health concerns.
  • Recognize persistent erectile symptoms warrant further clinical evaluation.
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form